Literature DB >> 23953078

Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes.

Stuart A Ross1.   

Abstract

Approximately half of patients with type 2 diabetes (T2D) do not achieve globally recognized blood glucose targets, despite the availability of a wide range of effective glucose-lowering therapies. Failure to maintain good glycemic control increases the risk of diabetes-related complications and long-term health care costs. Patients must be brought under glycemic control to improve treatment outcomes, but existing barriers to optimizing glycemic control must first be overcome, including patient nonadherence to treatment, the failure of physicians to intensify therapy in a timely manner, and inadequacies in the health care system itself. The reasons for such barriers include treatment side effects, complex treatment regimens, needle anxiety, poor patient education, and the absence of an adequate patient care plan; however, newer therapies and devices, combined with comprehensive care plans involving adequate patient education, can help to minimize barriers and improve treatment outcomes.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical inertia; Glycemic control; Nonadherence

Mesh:

Substances:

Year:  2013        PMID: 23953078     DOI: 10.1016/j.amjmed.2013.06.012

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  47 in total

1.  Safe and Effective Use of the Once Weekly Dulaglutide Single-Dose Pen in Injection-Naïve Patients With Type 2 Diabetes.

Authors:  Glenn Matfin; Kate Van Brunt; Alan G Zimmermann; Rebecca Threlkeld; Debra A Ignaut
Journal:  J Diabetes Sci Technol       Date:  2015-04-21

2.  Diabetes: safety and efficacy of albiglutide-results from two trials.

Authors:  Giuseppe Derosa; Pamela Maffioli
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

3.  Technology to overcome therapeutic inertia.

Authors:  Deborah A Greenwood; Malinda Peeples
Journal:  Mhealth       Date:  2019-01-08

4.  High burden of metabolic comorbidities in a citywide cohort of HIV outpatients: evolving health care needs of people aging with HIV in Washington, DC.

Authors:  M E Levy; A E Greenberg; R Hart; L Powers Happ; C Hadigan; A Castel
Journal:  HIV Med       Date:  2017-05-15       Impact factor: 3.180

5.  Patients' Future Expectations for Diabetes and Hypertension Treatments: "Through the Diet… I Think This is Going to Go Away."

Authors:  Paige C Fairchild; Aviva G Nathan; Michael Quinn; Elbert S Huang; Neda Laiteerapong
Journal:  J Gen Intern Med       Date:  2016-10-11       Impact factor: 5.128

6.  Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease.

Authors:  Jinnie J Rhee; Jialin Han; Maria E Montez-Rath; Sun H Kim; Mark R Cullen; Randall S Stafford; Wolfgang C Winkelmayer; Glenn M Chertow
Journal:  J Diabetes Complications       Date:  2019-09-03       Impact factor: 2.852

7.  A Behavioral Perspective of Therapeutic Inertia: A Look at the Transition to Insulin Therapy.

Authors:  Susan J Guzman
Journal:  Diabetes Spectr       Date:  2020-02

8.  Changes in metformin use and other antihyperglycemic therapies after insulin initiation in patients with type 2 diabetes.

Authors:  Scott J Pilla; James R Dotimas; Nisa M Maruthur; Jeanne M Clark; Hsin-Chieh Yeh
Journal:  Diabetes Res Clin Pract       Date:  2018-03-07       Impact factor: 5.602

9.  Patients With Type 2 Diabetes Are Willing to Do More to Overcome Therapeutic Inertia: Results From a Double-Blind Survey.

Authors:  Steven V Edelman; Richard Wood; Michelle Roberts; Jay H Shubrook
Journal:  Clin Diabetes       Date:  2020-07

Review 10.  Battle of GLP-1 delivery technologies.

Authors:  Minzhi Yu; Mason M Benjamin; Santhanakrishnan Srinivasan; Emily E Morin; Ekaterina I Shishatskaya; Steven P Schwendeman; Anna Schwendeman
Journal:  Adv Drug Deliv Rev       Date:  2018-07-21       Impact factor: 15.470

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.